RxDoctor Payments Data

O'Key Sams, MD

Internal Medicine · Fresno, CANPI 1760409726

Payments from drug & device makers

$2,097in general payments, 2019–2025

Across 118 payments — averaging $17.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$503
  • SK Life Science, Inc.$273
  • Neurocrine Biosciences, Inc.$181
  • Otsuka America Pharmaceutical, Inc.$126
  • Lundbeck LLC$103
  • Teva Pharmaceuticals USA, Inc.$81
  • plus $829 from 24 others

What the payments were for

  • Food & beverage$2,04497%
  • Education$533%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,097 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$325,188
Medicare patients
417
Services billed
4,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban376$129,878
Avonex (4 Pack)Interferon Beta-1a11$97,697
OzempicSemaglutide57$60,179
JardianceEmpagliflozin109$59,610
XareltoRivaroxaban205$48,343
TradjentaLinagliptin110$32,343
EntrestoSacubitril/Valsartan84$31,264
Sevelamer Carbonate75$28,649
JanuviaSitagliptin Phosphate42$28,115
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog186$27,658
RexultiBrexpiprazole43$27,333
XifaxanRifaximin13$19,379
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,618
NuedextaDextromethorphan Hbr/Quinidine22$16,841
LinzessLinaclotide26$15,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$129,878376 claims
BiogenAvonex (4 Pack)$21$97,69711 claims
Otsuka America Pharmaceutical, Inc.Rexulti$126$27,33343 claims
GSKTrelegy Ellipta, Breo Ellipta$41$24,60746 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$27$19,37913 claims
Avanir Pharmaceuticals, Inc.Nuedexta$74$16,84122 claims
Astellas Pharma US IncMyrbetriq$15$6,26925 claims
AstraZenecaLokelma$32$5,97916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →